Bolt Biotherapeutics (BOLT) AI Stock Analysis

• Market Cap: $9.67M
• Dividend Yield: N/A
• Average Volume (3M): 29.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: -62.68%
• EPS Growth: 23.94%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,919,441
• 10 Day Avg. Volume: 31,146
• 30 Day Avg. Volume: 29,181
• PEG Ratio: 0.66
• Price to Book (P/B): 7.14
• Price to Sales (P/S): 53.13
• P/FCF Ratio: -6.66
• Enterprise Value/Market Cap: -0.03
• Enterprise Value/Revenue: -0.01
• Enterprise Value/Gross Profit: -0.02
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $29.33
• Price Target Upside: 544.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $5.00 ▲(9.89% Upside)

Bolt Biotherapeutics faces significant challenges with profitability and cash flow, reflected in a low financial performance score. Technical indicators suggest bearish momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors contribute to a low overall stock score.

Positive Factors

Proprietary Platform

The Boltbody™ platform enhances cancer therapy efficacy, providing a competitive edge in immuno-oncology. This proprietary technology can drive long-term growth by improving treatment outcomes and expanding the company's product pipeline.

Strategic Partnerships

Strategic collaborations offer financial backing and resources, accelerating R&D and reducing risk. These partnerships can lead to milestone payments and royalties, supporting sustainable revenue growth and innovation.

Low Debt Levels

A low debt-to-equity ratio indicates a conservative leverage approach, enhancing financial stability. This allows Bolt to invest in R&D without significant financial strain, supporting long-term growth and operational flexibility.

Negative Factors

Negative Profit Margins

Significant losses and negative profit margins highlight ongoing profitability challenges. High operational expenses undermine financial performance, limiting the company's ability to generate sustainable profits and reinvest in growth.

Negative Cash Flow

Persistent negative cash flow indicates financial inefficiencies, constraining the company's ability to fund operations and growth initiatives. This ongoing challenge could impact Bolt's long-term financial health and strategic investments.

Revenue Decline

The recent revenue decline suggests potential challenges in maintaining growth momentum. This trend could affect Bolt's ability to achieve economies of scale and leverage its proprietary technologies for sustained market expansion.

Bolt Biotherapeutics Business Overview & Revenue Model

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

How the Company Makes Money

Bolt Biotherapeutics generates revenue primarily through the advancement of its proprietary drug candidates and strategic collaborations with pharmaceutical companies. The company's revenue model includes potential milestone payments from partnerships, royalties on future product sales, and funding from government grants and research institutions. Significant partnerships with larger biotech and pharmaceutical firms provide Bolt with financial support and resources to accelerate its research and development efforts, while also enabling shared risk in the development of new therapies. As Bolt progresses its clinical trials and achieves development milestones, it has the potential to unlock additional revenue streams through licensing agreements or partnerships.

Bolt Biotherapeutics Financial Statement Overview

Summary

Bolt Biotherapeutics shows modest revenue growth but faces significant profitability challenges with a negative net profit margin and ongoing cash flow inefficiencies. The balance sheet is stable with low debt, but the company struggles to generate returns for shareholders.

Income Statement

Bolt Biotherapeutics shows a modest revenue growth with a 34.3% increase from 2022 to 2023 and a slight decline of 2.4% from 2023 to 2024. However, the company has been experiencing significant losses with a negative net profit margin of -820.7% in 2024. The gross profit margin is stable at 100% for 2024, indicating that cost of goods sold is negligible compared to revenue, but high operational expenses continue to weigh down profitability.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio of 0.44 in 2024, suggesting a conservative leverage approach. However, return on equity remains negative due to consistent losses, indicating inefficiencies in generating returns for shareholders. The equity ratio stands at 57.4%, reflecting a stable financial structure with more than half of its assets funded by equity.

Cash Flow

Operating cash flow remains negative, but improved slightly from -69.5 million in 2023 to -61.3 million in 2024. Free cash flow also increased marginally to -61.3 million, indicating ongoing challenges in cash generation. The operating cash flow to net income ratio of 0.97 suggests that cash flow is closely aligned with net losses, while free cash flow to net income ratio mirrors this trend.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.26M	7.69M	7.88M	5.73M	1.26M	231.00K
Gross Profit	12.37M	5.51M	5.99M	838.00K	-2.41M	-40.13M
EBITDA	-52.09M	-66.45M	-74.34M	-88.66M	-91.59M	-48.57M
Net Income	-50.71M	-63.12M	-69.20M	-85.88M	-104.39M	-72.27M
Balance Sheet
Total Assets	75.50M	99.63M	159.78M	227.81M	307.72M	46.54M
Cash, Cash Equivalents and Short-Term Investments	34.77M	47.32M	102.19M	168.89M	186.22M	22.84M
Total Debt	24.18M	25.21M	20.22M	22.61M	24.36M	10.88M
Total Liabilities	36.66M	42.43M	47.04M	56.30M	57.60M	151.49M
Stockholders Equity	38.84M	57.20M	112.74M	171.51M	250.12M	-104.95M
Cash Flow
Free Cash Flow	-51.40M	-61.33M	-69.73M	-78.46M	-59.40M	-50.57M
Operating Cash Flow	-51.36M	-61.29M	-69.53M	-76.50M	-57.07M	-47.31M
Investing Cash Flow	54.71M	57.58M	71.04M	57.86M	-232.20M	-20.59M
Financing Cash Flow	43.00K	108.00K	253.00K	503.00K	311.11M	39.60M

Bolt Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 4.55 is below the 20-day moving average (MA) of 5.62, below the 50-day MA of 5.47, and below the 200-day MA of 6.73, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 32.56 is Neutral, neither overbought nor oversold. The STOCH value of 3.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.

Bolt Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	45 Neutral	$9.67M	-0.19	-81.33%	―	-62.68%	23.94%
XBIO	43 Neutral	$6.49M	-1.43	-51.83%	―	-2.94%	34.52%
LYRA	41 Neutral	$7.58M	-0.16	-238.26%	―	-57.69%	63.76%
INAB	34 Underperform	$7.49M	-0.16	-165.56%	―	―	70.57%
MBIO	31 Underperform	$8.83M	―	―	―	―	97.92%

Bolt Biotherapeutics Corporate Events

Bolt Biotherapeutics’ Pioneering Study on BDC-4182: A New Hope for Cancer Treatment

In a promising development for cancer treatment, Bolt Biotherapeutics, Inc. (BOLT) is conducting a groundbreaking study titled ‘A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer.’ The study aims to evaluate the safety and efficacy of BDC-4182, a novel drug designed to treat advanced gastric and gastroesophageal cancers, marking a significant step in cancer therapeutics.

Bolt Biotherapeutics Announces Major Restructuring Plan

On October 1, 2025, Bolt Biotherapeutics announced a restructuring plan to reduce operating expenses, including a 50% workforce reduction, to extend its cash runway into 2027. The company also provided an update on its Phase 1 study of BDC-4182, observing a strong immune response at initial dose levels and planning to modify the trial protocol for step-up dosing, with initial clinical data expected in the third quarter of 2026.

The most recent analyst rating on (BOLT) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.

Bolt Biotherapeutics Reports Reduced Losses and Revenue Growth

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment, leveraging its expertise in myeloid biology to enhance the immune system’s response against tumors. In its latest earnings report for the quarter ending June 30, 2025, the company highlighted key financial metrics and strategic developments. The company reported a net loss of $8.6 million for the quarter, a significant improvement compared to the $21.2 million loss in the same period last year. This reduction in losses was primarily due to decreased operating expenses, which fell from $23.9 million to $11.0 million, reflecting a strategic restructuring and cost management efforts. Despite the ongoing challenges, Bolt Biotherapeutics reported collaboration revenue of $1.8 million, up from $1.3 million in the previous year, indicating progress in its partnerships. Looking ahead, the company remains focused on advancing its clinical programs and securing additional capital to sustain operations through mid-2026, as it navigates uncertainties in the macroeconomic environment and the biopharmaceutical industry.